Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases in the United States. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, and traumatic brain injury, as well as for daily health. Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. It also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPSA, a blend of NanoStilbene and broccoli sprout extracts; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. In addition, the company develops therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology; and portfolio of immunotherapies that provides dendritic cell vaccines for cancers to Parkinson's disease developed on StemVacs platform. Therapeutic Solutions International, Inc. was founded in 2007 and is headquartered in Elk City, Idaho.
| 0.0007 | |
| 0.0008 | |
| - | |
| 0.0009 | |
| 0.0007 | |
| 0.0004-0.0022 | |
| 3 907 K | |
| 4 884 M | |
| 91 382 | |
| -0.0001 | |
| 1.632 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ELK CITY, Idaho, July 31, 2023--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. (TSOI), announced today issuance of a Notice of Allowance from the United States Patent and Trademark Office ...
Protection of T Cells from Tumor-Induced Suppression Suggests Potential for Enhancing Efficacy of Checkpoint Inhibitor and CAR-T Therapies Company Plans to Initiate Phase I/II Clinical Trial in Advan...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
